Last reviewed · How we verify
Plasma-derived AT-III concentrate — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Plasma-derived AT-III concentrate (Plasma-derived AT-III concentrate) — Grifols Biologicals, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Plasma-derived AT-III concentrate TARGET | Plasma-derived AT-III concentrate | Grifols Biologicals, LLC | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Plasma-derived AT-III concentrate CI watch — RSS
- Plasma-derived AT-III concentrate CI watch — Atom
- Plasma-derived AT-III concentrate CI watch — JSON
- Plasma-derived AT-III concentrate alone — RSS
Cite this brief
Drug Landscape (2026). Plasma-derived AT-III concentrate — Competitive Intelligence Brief. https://druglandscape.com/ci/plasma-derived-at-iii-concentrate. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab